Manali Kamdar - Concepedia

Author

Manali Kamdar

Also Known As

CH Li, Douglas Joshua, Kamdar, M., Kamdar, Manali, M Kamdar, M. Kamdar, Manali K. Kamdar, Manali Kamdar, Manali Kirtikumar Kamdar

254

Publications

6.5K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Denver University of Colorado Cancer Center Memorial Sloan Kettering Cancer Center The University of Texas MD Anderson Cancer Center Fred Hutch Cancer Center

About

Manali Kamdar is an author at University of Colorado Denver specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	21	2.3K
2	Immunology	14	15	1.5K
3	Health Sciences	11	12	1.1K
4	Cellular Therapies	4	4	81
5	Blood Transplantation	1	1	14

Manali Kamdar

Publications

5.8K

Citations

H-Index

Page 1

	Year	Citations
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers, Journal of Clinical Oncology	2019	741
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial Manali Kamdar, Scott R. Solomon, Jon Arnason, The Lancet Second-line TreatmentSalvage ChemotherapyInterim AnalysisLymphoid NeoplasiaTransplantation	2022	704
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, The Lancet Hematological MalignancyLymphoid NeoplasiaOncologyImmunologyHematology	2020	583
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma Marcelo C. Pasquini, Zhen‐Huan Hu, Kevin J. Curran, Blood Advances	2020	421
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Blood ImmunologyPathologyGlobal Phase 3PharmacotherapyPrimary Refractory	2022	327
Outcomes of COVID-19 in patients with CLL: a multicenter international experience Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna, Blood	2020	316
PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD Bradley M. Haverkos, Diana Abbott, Mehdi Hamadani, Blood	2017	239
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. William G. Wierda, John C. Byrd, Jeremy S. Abramson, PubMed Hematological MalignancyLymphoid NeoplasiaVersion 4.2020Chronic Lymphocytic LeukemiaMedicine	2020	143
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers Andrew M. Evens, Alexey V. Danilov, Deepa Jagadeesh, Blood	2021	122
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy Jennifer L. Crombie, Tara Graff, Lorenzo Falchi, Blood	2024	106

Page 1